Pfizer main competitors are Novartis, Bristol-Myers Squibb, and Eli Lilly and Company.
Competitor Summary. See how Pfizer compares to its main competitors:
|Company||Founding Date||Zippia Score||Headquarters||# of Locations||Revenue||Employees|
|New York, NY||18||$100.3B||78,500|
|New York, NY||13||$46.2B||30,000|
|New Brunswick, NJ||26||$94.9B||134,500|
|East Hanover, NJ||16||$49.9B||110,000|
|New York, NY||4||$18.0B||34,500|
|Company||Highest Salary||Hourly Salary|
Eli Lilly and Company
The Dow Chemical Company
Johnson & Johnson
The J.M. Smucker Co.
|Eli Lilly and Company||53%||47%|
|Company||White||Hispanic or Latino||Black or African American||Asian||Unknown||Diversity Score|
Dr. Caforio has been our Chief Executive Officer since May 2015. He was our Chief Executive Officer Designate from January to May 2015, our Chief Operating Officer from June 2014 to May 2015, and he served as Executive Vice President and Chief Commercial Officer from November 2013 to June 2014. From October 2011 to November 2013, he served as President, U.S. He held the position of Senior Vice President, Global Commercialization and Immunology from May 2010 to October 2011. Prior to that, he served as Senior Vice President, Oncology, U.S. and Global Commercialization from March 2009 to May 2010. From January 2007 to March 2009 he served as Senior Vice President, U.S. Oncology and from May 2004 to January 2007, he served as Senior Vice President, European Marketing and Brand Commercialization. Dr. Caforio is a member of the Board of Trustees of Hun School of Princeton and a member of the Business Roundtable, CEO Roundtable on Cancer and the Pharmaceutical Research and Manufacturers of America (PhRMA) and The Prium.
Mr. Wallace became President and Chief Executive Officer in April 2019 after having been President and Chief Operating Officer from July 2018 to April 2019, responsible for all of the Company’s operating units worldwide. He joined Colgate-Palmolive in 1987 and progressed through a number of global positions in marketing and general management. In 2002, he was appointed to Vice President and General Manager of the Global Toothbrush Division. Following that assignment he led the Colgate business in Mexico and in 2010, became President, Colgate North America, including responsibility for Colgate’s Global Sustainability strategy.
Mark Costa is a Board Member at American Chemistry Council, Chairman at EASTMAN CHEMICAL CO, and Senior Vice President at Polymers Group and is based in Johnson City, Tennessee. He has worked as Exec VP:Speciality Polymers at EASTMAN CHEMICAL CO, Senior VP:Corp Strategy at EASTMAN CHEMICAL CO, and Senior Partner:Integrated North American at Monitor Group. Mark attended Harvard Business School and University of California Berkeley.
I'm the chairman and CEO of Eli Lilly and Company, after holding management roles in the U.S., Canada and China, as well as running Lilly’s largest business unit. Before I joined Lilly in 1996, I worked as an account rep at IBM. I'm on the board of Adobe, and I'm chairman of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). I also serve on the board of the Central Indiana Corporate Partnership. I'm a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) CEO Steering Committee, The Business Council, Business Roundtable and the National Council for Expanding American Innovation (NCEAI). I serve on the Riley Children’s Foundation’s board of governors. I am a digital media spokesperson for Lilly and discuss topics related to our company, our business and the health care environment. We operate in a highly regulated environment, and only designated employees can discuss our products or pipeline. If you need information about our products or have questions or concerns, please visit these resources: https://e.lilly/guidelines
Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.
Mark Smucker is a President & CEO at J M SMUCKER CO and is based in Orrville, Ohio. He has worked as General Manager, Mercosur at J M SMUCKER CO; Vice President and General Manager, International Markets at J M SMUCKER CO; and Teacher, Eighth Grade Science at Montgomery Academy. Mark attended Thunderbird School of Global Management between 1994 and 1996 and College of William & Mary until 1992.